Fractyl Health, Inc. (GUTS)
$4.03-8.62%Close
SELLCRISIS · day 25
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $291M
- Beta
- 2.42
- P/E (TTM)
- -0.30
- Short % float
- 7.32%
- Days to cover
- 1.2
- SI change
- -20.3%
- 1W
- -11.82%
- 1M
- -45.10%
- vs SPY 1W
- -11.68%
- vs SPY 1M
- -47.60%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 7
- VALUE
- 6
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-128.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.30
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-31.96
P/FCF-
EV/EBITDA-0.64
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO3.15
ND/EBITDA-
BETA2.42
Company news
FAQ
- What is LOPJLB’s current signal on GUTS?
- LOPJLB’s latest quantitative signal on Fractyl Health, Inc. (GUTS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is GUTS in?
- Fractyl Health, Inc. (GUTS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Fractyl Health, Inc. (GUTS) do?
- Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel a…